Dateline City:
KENILWORTH, N.J.
Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today study findings demonstrating that KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, achieved an overall
response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with
follow-up of up to 27 months in patients with relapsed or refractory
primary mediastinal large B-cell lymphoma (PMBCL), a type of non-Hodgkin
lymphoma, who were ineligible for or failed to respond to autologous
stem-cell transplantation (ASCT).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more